How to Access Affordable GLP-1 Weight-Loss Drugs: Insurance Coverage, Patient Assistance Programs, and Cost Comparison Strategies
GLP-1 weight-loss drugs like Ozempic and Wegovy can cost over $1,000 per month without help — but most people never explore every option available to them. This guide breaks down insurance coverage rules, manufacturer savings programs, and comparison strategies that can reduce your out-of-pocket costs significantly.
The Real Cost Problem With GLP-1 Medications
The promise of GLP-1 receptor agonists is genuine. Clinical trials published in the New England Journal of Medicine showed semaglutide (Wegovy) produced an average weight loss of 14.9% of body weight over 68 weeks — results that were previously only achievable through bariatric surgery. Yet the drug's list price sits around $1,349 per month in the United States, making it one of the most expensive chronic medications on the market.
According to KFF Health News, approximately 1 in 8 American adults has now tried a GLP-1 drug, yet access follows a deeply unequal pattern. Higher-income, privately insured patients are far more likely to receive coverage than Medicaid recipients or uninsured individuals — a disparity that has become a defining tension in modern healthcare equity.
The core issue: these drugs are approved by the FDA for both Type 2 diabetes and chronic weight management, but insurers and federal programs treat those two indications very differently. Understanding where you fall in that system is the first step toward reducing what you actually pay.
Understanding Insurance Coverage for GLP-1 Drugs
Private Insurance: What to Check First
Private employer-sponsored plans and marketplace plans vary enormously. Some plans cover semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) without restriction; others require prior authorization, step therapy (trying cheaper drugs first), or a documented BMI threshold, typically 30 or higher, or 27 with a qualifying comorbidity.
Before assuming you're not covered, request your plan's drug formulary — specifically Tier 3 and Tier 4 listings — and ask your insurer whether your diagnosis code (obesity vs. diabetes) changes coverage status. A prescriber who documents obesity as a chronic disease rather than a lifestyle issue can sometimes unlock different formulary pathways.
Medicare Coverage: A Significant 2024 Change
Historically, Medicare Part D was prohibited by law from covering drugs used solely for weight loss. That changed in 2024. Following updated FDA labeling that approved semaglutide (Wegovy) to reduce cardiovascular risk in obese or overweight patients with established heart disease, CMS issued guidance confirming that Medicare Part D plans may now cover Wegovy for that cardiovascular indication.
This is a narrow but meaningful opening. According to CMS.gov, the coverage applies when the drug is prescribed to reduce major adverse cardiovascular events — not for weight management alone. If you have Medicare and a documented history of cardiovascular disease alongside obesity, ask your cardiologist or primary care physician whether you qualify under this pathway. You can verify your specific Part D plan's formulary directly through the CMS Medicare drug coverage resource page.
Medicaid: The Widest Gap
Medicaid coverage is determined state by state, and most states still exclude GLP-1 drugs for obesity treatment. A 2023 KFF analysis found that fewer than half of state Medicaid programs cover any GLP-1 medication for weight management purposes, even when clinical necessity is documented. Diabetes diagnoses are treated more generously, meaning access often depends on whether a patient's chart reflects metabolic disease.
Manufacturer Patient Assistance and Savings Programs
Novo Nordisk Programs (Ozempic, Wegovy)
Novo Nordisk operates two distinct programs that are frequently confused. The Novo Nordisk Patient Assistance Program (PAP) provides free medication to uninsured or underinsured patients who meet income eligibility thresholds — generally at or below 400% of the federal poverty level. Applications are submitted through NovoCare, the company's patient support platform.
Separately, the Wegovy Savings Card for commercially insured patients can reduce monthly costs to as low as $0 for eligible individuals, though the program caps savings over time and excludes government-insured patients (Medicare, Medicaid, TRICARE). According to Novo Nordisk's published program terms, patients must have commercial insurance that covers the drug for the $0 offer to apply.
Eli Lilly Programs (Mounjaro, Zepbound)
Eli Lilly's Lilly Insulin Value Program — originally designed for insulin access — has an adjacent structure for GLP-1 medications. The Zepbound Savings Card has offered eligible commercially insured patients monthly costs as low as $25, while the Lilly Cares Foundation provides uninsured patients access to a Patient Assistance Program based on income qualification.
Importantly, Eli Lilly introduced single-dose vials of tirzepatide in 2024 at a lower list price point specifically to address access concerns — priced around $399–$549 per month depending on dose, compared to the standard Zepbound list price of roughly $1,060. This self-pay option is significant for uninsured individuals who earn too much to qualify for PAP programs.
Compounded Semaglutide and Tirzepatide: What to Know
During periods of FDA-designated drug shortage, compounding pharmacies were legally permitted to produce copies of semaglutide and tirzepatide. Compounded versions circulated widely at $200–$500 per month — dramatically cheaper than brand-name alternatives. However, the FDA removed both drugs from the official shortage list in early 2025, which legally requires compounding pharmacies to cease production of these specific compounds for most patients.
This is a rapidly evolving regulatory space. As of mid-2025, enforcement timelines and legal challenges from compounding pharmacies are ongoing. Patients considering compounded GLP-1 options should verify current FDA status and confirm a pharmacy's 503B outsourcing facility registration before proceeding. The quality and dosing consistency of compounded formulations is not FDA-verified, which carries real clinical risk.
Cost Comparison Strategies That Actually Work
Use a GLP-1 Cost Calculator Before You Fill
One of the most underused tools in managing GLP-1 costs is a purpose-built cost calculator that accounts for your insurance type, income level, and available savings programs simultaneously. Before you accept the sticker price at a pharmacy window, run your scenario through the GLP-1 Cost Calculator at glp1costcalculator.com to estimate what you'd actually pay across different coverage scenarios.
Many patients discover they qualify for savings they weren't told about at the point of prescribing. Physicians rarely have time to navigate the full landscape of manufacturer programs, formulary tiers, and copay cards — that due diligence falls to patients.
GoodRx, Costco, and Mark Cuban's Cost Plus Drugs
GLP-1 drugs are not yet available generically, which limits discount platforms significantly. However, GoodRx coupons can reduce costs at certain pharmacies for specific formulations, and Costco Pharmacy has historically offered some of the lowest cash prices on brand-name medications due to its bulk purchasing model.
Cost Plus Drugs (costplusdrugs.com), launched by Mark Cuban, currently does not list semaglutide or tirzepatide due to manufacturer restrictions — but it's worth monitoring as the landscape evolves. For patients on metformin or other GLP-1 adjacent medications used in combination protocols, Cost Plus Drugs offers significant savings.
Telehealth Platforms and Bundled Pricing
Several telehealth companies — including Hims & Hers, Ro, and WeightWatchers Clinic — have offered bundled GLP-1 prescriptions that include provider consultation fees. Bundled pricing sometimes obscures the true per-drug cost, so always break down what you're paying for the medication itself versus the clinical service. Use the GLP-1 Cost Calculator to benchmark telehealth quotes against standard pharmacy pricing.
Frequently Asked Questions About GLP-1 Drug Costs
Does Medicare Part D cover Wegovy for weight loss?
Not for weight loss alone. Medicare Part D coverage for Wegovy currently applies only when prescribed to reduce cardiovascular events in patients with obesity or overweight and established cardiovascular disease, per updated CMS guidance following the SELECT trial results. Pure weight management without cardiovascular indication remains excluded under current federal law.
What income level qualifies for GLP-1 patient assistance programs?
Eligibility varies by manufacturer, but most PAP programs target patients at or below 400% of the federal poverty level — roughly $58,000 for an individual in 2025. Some programs extend eligibility higher when the patient is underinsured (has insurance that doesn't cover the specific drug). You must apply directly through each manufacturer's portal and provide proof of income and insurance status.
Is compounded semaglutide still legal to obtain?
As of early 2025, the FDA has removed semaglutide and tirzepatide from the official shortage list, which restricts compounding pharmacy production for most patients. Legal compounding may still apply in specific circumstances — such as patients with documented allergies to brand formulation components — but the broad availability seen in 2023–2024 has legally narrowed. Consult your physician and verify any pharmacy's current compliance status before purchasing.
How much can a savings card actually reduce my monthly cost?
For commercially insured patients whose plan covers the drug, manufacturer savings cards can reduce monthly costs to as low as $0 (Novo Nordisk) or $25 (Eli Lilly) for qualifying individuals. These programs have annual caps and income eligibility requirements. For uninsured patients, savings cards typically do not apply — the PAP route is more appropriate for that group.
A Strategic Approach to Lowering Your Costs
The inequality embedded in GLP-1 access is real and documented. But within the current system, there are meaningful levers available: understanding your specific formulary, applying for manufacturer programs before giving up on coverage, exploring the cardiovascular indication pathway if applicable, and using cost benchmarking tools to avoid overpaying.
Start by confirming your diagnosis code and insurance tier status with your prescriber. Then check manufacturer PAP eligibility before filling at full price. If you're comparing across drugs, doses, or pharmacies, running those numbers through a structured cost calculator will surface differences that phone calls and pharmacy counters rarely surface on their own.